Commencing international collaboration for clinical integration in aesthetic healthcare in Asia following MOU
IRVINE, Calif. -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced that it hosted two dermatologists from Chulabhorn International College of Medicine (Thammasat University, "CICM") in Bangkok, Thailand, for clinic site visits and academic exchange.
This initiative follows the Memorandum of Understanding (MOU) signed in November 2025 to promote academic collaboration and international exchange. The visit marks the first step in a strategic international partnership between CICM, a leading international medical education institution in the ASEAN region, and SBC Medical, which supports one of the largest clinic networks in Japan.
CICM is a prominent international medical education institution in the ASEAN region, recognized for its excellence in both clinical and basic medical science. Its mission to develop medical professionals with an international perspective aligns with SBC Medical’s commitment to expanding safe and innovative medical services from Asia to the world. This shared vision led to the conclusion of the MOU in November 2025, focusing on advancing academic cooperation in education and research.
Details of the Academic Exchange
As part of the concrete actions agreed upon following the MOU, two dermatologists from CICM visited Japan to engage with SBC Medical’s specialists, including Dr. Ayaka Nishikawa, Executive Director of Dermatology at Shonan Beauty Clinic. The exchange focused on the following areas:
・Operational Site Visits: Observing clinical operations at Shonan Beauty Clinic and other affiliated facilities.
・Educational Sessions: Participating in physician training programs supported by SBC Medical.
・Clinical Discussions: Sharing insights on treatment protocols for Asian skin types and discussing best practices in risk management.
SBC Medical remains dedicated to deepening international partnerships and joint research initiatives, such as those with CICM, to integrate the latest clinical insights into the group and foster medical talent with global perspectives. As a leading medical group in Asia, the Company will continue to strengthen its global foundation for medical education and research, striving for safety, transparency, and sustainable value enhancement. For more information regarding the MOU with CICM, please refer to our previous announcement.
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.